Zenas BioPharma Crashes 53% Despite Meeting Trial Goals—Why Investors Aren't Buying It

Zenas BioPharma stock plunges over 50% after Phase 3 obexelimab trial results disappoint Wall Street, despite meeting all endpoints in rare autoimmune disease study.